James Paul Kastenmayer - 23 Feb 2023 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Reporting relationship: General Counsel
Issuer ticker: SYRE
Reported as of: 23 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Feb 2023, 17:24:11 UTC
Prior SEC filing: 25 Aug 2022
Next SEC filing: 25 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ James Kastenmayer

Key filing fact

James Paul Kastenmayer filed Form 4 for Aeglea BioTherapeutics, Inc. (SYRE) on 24 Feb 2023.

Key facts

This page summarizes James Paul Kastenmayer's Form 4 filing for Aeglea BioTherapeutics, Inc. (SYRE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Feb 2023, 17:24.

Change

Previous filing in this sequence was filed on 25 Aug 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGLE transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +500,000
Change %
Price: $0.000000
Shares after: 500,000
Date: 23 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $0.4400
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 23, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.